Bio-Rad Laboratories Inc. has won an injunction excluding competitor 10x Genomics Inc. from marketing products that perform genetic analysis on a single-cell droplet platform.

Wednesday's decision from U.S. District Judge Richard Andrews of the District of Delaware follows a jury trial last fall that ended in a $24 million patent infringement award for Hercules, California-based Bio-Rad and the University of Chicago, from whom it licenses the patents. 10X managed to turn back Bio-Rad's request for enhanced damages and attorney fees.

According to Andrews' opinion, Pleasanton, California-based 10X's single-cell products account for more than 80% of its sales. Bio-Rad and the university “have shown that they will suffer irreparable competitive harm absent an injunction,” Andrews wrote. ”Plaintiffs are being forced to compete with 10x's products that incorporate and infringe their own patented inventions.”